Evonik unveils probiotic advance in fight against antibiotic resistance

Evonik researchers say they have achieved a significant breakthrough with Ecobiol

AstraZeneca gets CDSCO nod for Trastuzumab Deruxtecan plus Pertuzumab

Approval expands treatment options for patients with unresectable or metastatic HER2-positive breast cancer

Hoola Health raises $5 million to expand child-centric paediatric care

Bengaluru-based startup will use the fresh capital to enter new markets, enhance technology capabilities, and scale its integrated care model

Novo Nordisk’s CagriSema delivers strong Phase 3 results across REIMAGINE diabetes trials

Eli Lilly's oral weight-loss drug shows major fat loss across stages of menopause in trials

The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions

Ayushman Bharat achieves full national coverage as West Bengal gets onboard

Nearly 1.43 crore families in West Bengal to benefit as India’s flagship health assurance scheme achieves full national coverage across all States and Union Territories

AstraZeneca reports major Phase III breakthrough in IgA kidney disease trial

At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint

Group Mangalam enters India’s wellness market with launch of Neat Everyday

The company has announced its entry into India’s rapidly expanding nutraceuticals and wellness sector with the launch of Neat Everyday, a new consumer wellness brand

Lilly’s oral GLP-1 drug Orforglipron outperforms Semaglutide in phase 3 diabetes trial

Based on the cumulative data from ACHIEVE-1 through ACHIEVE-5, Lilly plans to submit orforglipron for FDA approval for the treatment of type 2 diabetes by the end of the second quarter

FDA expands Pfizer’s HYMPAVZI approval

Broadening access for children & patients with inhibitor-complicated hemophilia